NEW ZEALAND DATA SHEET

1. PRODUCT NAME
NORVASC® 5 mg and 10 mg tablets

2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 5 mg coated tablet contains amlodipine besilate equivalent to 5 mg amlodipine.
Each 10 mg coated tablet contains amlodipine besilate equivalent to 10 mg amlodipine.
For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM
NORVASC 5 mg tablets are white to off-white emerald-shaped scored tablets, marked with NVC/5 on one side and Pfizer on the other, or engraved “AML 5” and breaker score on one side and “Pfizer” logo on the other side.
NORVASC 10 mg tablets are white to off-white emerald-shaped scored tablets, marked with NVC/10 on one side and Pfizer on the other, or engraved “AML-10” on one side and “Pfizer” logo on the other side.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications
NORVASC is indicated for the first-line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. Patients not adequately controlled on a single antihypertensive agent may benefit from the addition of NORVASC, which has been used in combination with a thiazide diuretic, beta adrenoceptor blocking agent, or an angiotensin-converting enzyme inhibitor.
NORVASC is indicated for the first-line treatment of myocardial ischaemia, whether due to fixed obstruction (stable angina) and/or vasospasm/vasoconstriction (Prinzmetal’s or variant angina) of coronary vasculature. NORVASC may be used where the clinical presentation suggests a possible vasospastic/vasoconstrictive component but where vasospasm/vasoconstriction has not been confirmed. NORVASC may be used alone as monotherapy, or in combination with other antianginal drugs in patients with angina that is refractory to nitrates and/or beta-blockers.

4.2 Dose and method of administration

Dose
For both hypertension and angina, the usual initial dose is 5 mg NORVASC once-daily which may be increased to a maximum dose of 10 mg depending on the individual patient’s response.
No dose adjustment of NORVASC is required upon concomitant administration of thiazide diuretics, beta-blockers and angiotensin-converting enzyme (ACE) inhibitors.

**Elderly**

The time to reach peak plasma concentrations of amlodipine is similar in elderly and younger subjects. Amlodipine clearance tends to be decreased with resulting increases in AUC and elimination half-life in elderly patients.

Increases in AUC and elimination half-life in patients with congestive heart failure were as expected for the patient age group studied.

NORVASC, used at similar doses in elderly or younger patients, is equally well tolerated. Therefore normal dosage regimens are recommended.

**Renal Impairment**

Amlodipine is extensively metabolised to inactive metabolites with 10% excreted as unchanged drug in the urine. Changes in amlodipine plasma concentrations are not correlated with the degree of renal impairment. NORVASC may be used at normal doses in patients with renal failure. Amlodipine is not dialysable.

**Paediatric population**

NORVASC is not recommended for use in children.

4.3 CONTRAINDICATIONS

NORVASC is contraindicated in patients with a known hypersensitivity to amlodipine, other dihydropyridines, or any of the inactive ingredients.

4.4 Special warnings and precautions for use

**Patients with Heart Failure**

In a long-term placebo-controlled study (PRAISE-2) of amlodipine in patients with New York Heart Association (NYHA) class III and IV heart failure of non-ischaemic aetiology, amlodipine was associated with increased reports of pulmonary oedema despite no significant difference in the incidence of worsening heart failure compared to placebo (see section 5.1, Patients with Heart Failure).

**Hepatic Impairment**

As with all calcium channel blockers, amlodipine’s half-life is prolonged in patients with impaired liver function and dosage recommendations have not been established. The compound should therefore be administered with caution in these patients.

**Paediatric Use**

Safety and effectiveness of amlodipine in children have not been established.
4.5 Interaction with other medicines and other forms of interaction

NORVASC has been safely administered with thiazide diuretics, beta-blockers, alpha blockers, ACE inhibitors, long-acting nitrates, sublingual glyceryl trinitrate, non-steroidal anti-inflammatory agents, antibiotics, and oral hypoglycaemic agents.

In vitro data from studies with human plasma indicate that amlodipine has no effect on protein binding of the drugs tested (digoxin, phenytoin, warfarin, or indomethacin).

Simvastatin: Co-administration of multiple doses of 10 mg amlodipine with 80 mg simvastatin resulted in a 77% increase in exposure to simvastatin compared to simvastatin alone. Limit the dose of simvastatin to 20 mg daily in patients on amlodipine.

Grapefruit Juice: Administration of amlodipine with grapefruit or grapefruit juice is not recommended as bioavailability may be increased in some patients, resulting in increased blood pressure lowering effects.

CYP3A4 Inhibitors: With concomitant use with the CYP3A4 inhibitor erythromycin in young patients and diltiazem in elderly patients, the plasma concentration of amlodipine was increased. The clinical relevance of this finding is uncertain. It cannot be ruled out that strong inhibitors of CYP3A4 (e.g. ketoconazole, itraconazole, ritonavir) may increase the plasma concentrations of amlodipine to a greater extent than diltiazem. Amlodipine should be used with caution when administered with CYP3A4 inhibitors.

Clarithromycin: Clarithromycin is an inhibitor of CYP3A4. There is an increased risk of hypotension in patients receiving clarithromycin with amlodipine. Close observation of patients is recommended when amlodipine is co-administered with clarithromycin.

CYP3A4 Inducers: There are no data available regarding the effect of CYP3A4 inducers on amlodipine. Concomitant use of CYP3A4 inducers (e.g. rifampicin, Hypericum perforatum (St John’s Wort)) may decrease the plasma concentrations of amlodipine. Amlodipine should be used with caution when administered with CYP3A4 inducers.

Special Studies: Effect of Other Agents on Amlodipine

Cimetidine: Co-administration of amlodipine with cimetidine did not alter the pharmacokinetics of amlodipine.

Aluminium/Magnesium (Antacid): Co-administration of an aluminium/magnesium antacid with a single dose of amlodipine had no significant effect on the pharmacokinetics of amlodipine.

Sildenafil: A single 100 mg dose of sildenafil in subjects with essential hypertension had no effect on the pharmacokinetic parameters of amlodipine. When amlodipine and sildenafil were used in combination, each agent independently exerted its own blood pressure lowering effect.

Special Studies: Effect of Amlodipine on Other Agents

Atorvastatin: Co-administration of multiple 10 mg doses of amlodipine with 80 mg atorvastatin resulted in no significant change in the steady-state pharmacokinetic parameters of atorvastatin.
**Digoxin**: Co-administration of amlodipine with digoxin did not change serum digoxin levels or digoxin renal clearance in healthy volunteers.

**Ethanol (Alcohol)**: Single and multiple 10 mg doses of amlodipine had no significant effect on the pharmacokinetics of ethanol.

**Warfarin**: Co-administration of amlodipine with warfarin did not change the warfarin prothrombin response time.

**Cyclosporin**: No drug interaction studies have been conducted with cyclosporin and amlodipine in healthy volunteers or other populations, with the exception of renal transplant patients. Various studies in renal transplant patients report that co-administration of amlodipine with cyclosporin affects the trough concentrations of cyclosporin, from no change up to an average increase of 40%. Consideration should be given for monitoring cyclosporin levels in renal transplant patients on amlodipine.

**Tacrolimus**: There is a risk of increased tacrolimus blood levels when co-administered with amlodipine. In order to avoid toxicity of tacrolimus, administration of amlodipine in a patient treated with tacrolimus requires monitoring of tacrolimus blood levels and dose adjustment of tacrolimus when appropriate.

**Mechanistic Target of Rapamycin (mTOR) Inhibitors**: mTOR inhibitors such as sirolimus, temsirolimus, and everolimus are CYP3A substrates. Amlodipine is a weak CYP3A inhibitor. Concomitant use of mTOR inhibitors and amlodipine may increase exposure of mTOR inhibitors.

### 4.6 Fertility, pregnancy and lactation

**Fertility**

There was no effect on the fertility of rats treated with amlodipine.

**Pregnancy**

Category C.

The safety of amlodipine in human pregnancy or lactation has not been established. Amlodipine did not demonstrate any fetotoxic or teratogenic potential in animal reproductive studies other than delay in parturition and prolongation of labour in rats at a dose level 50 times the maximum recommended dose in humans. No mutagenic activity has been found in tests for gene mutations or cytogenic assays. Accordingly, use in pregnancy is recommended only when there is no safer alternative and when the disease itself carries greater risk for the mother and fetus.
**Lactation**

Experience in humans indicates that amlodipine is transferred into human breast milk. The median amlodipine concentration ratio of milk/plasma in 31 lactating women with pregnancy-induced hypertension was 0.85 following amlodipine administration at an initial dose of 5 mg once daily which was adjusted as needed (mean daily dose and body weight adjusted daily dose: 6 mg and 98.7 mcg/kg, respectively). The estimated daily dose of amlodipine in the infant via breast milk was 4.17 mcg/kg.

**4.7 Effects on ability to drive and use machinery**

Clinical experience with amlodipine indicates that it is unlikely to impair a patient’s ability to drive or use machinery.

**4.8 Undesirable effects**

NORVASC is well-tolerated. In placebo-controlled clinical trials involving patients with hypertension or angina, the most commonly observed adverse effects were:

<table>
<thead>
<tr>
<th>MedDRA System Organ Class</th>
<th>Undesirable Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nervous System Disorders</td>
<td>Headache, dizziness, somnolence</td>
</tr>
<tr>
<td>Cardiac Disorders</td>
<td>Palpitations</td>
</tr>
<tr>
<td>Vascular Disorders</td>
<td>Flushing</td>
</tr>
<tr>
<td>Gastrointestinal Disorders</td>
<td>Abdominal pain, nausea</td>
</tr>
<tr>
<td>General Disorders and Administration Site Conditions</td>
<td>Oedema, fatigue</td>
</tr>
</tbody>
</table>

In these clinical trials no pattern of clinically significant laboratory test abnormalities related to amlodipine has been observed.

Less commonly observed adverse effects in marketing experience include:

<table>
<thead>
<tr>
<th>MedDRA System Organ Class</th>
<th>Undesirable Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood and Lymphatic System Disorders</td>
<td>Leucopenia, thrombocytopenia</td>
</tr>
<tr>
<td>Metabolism and Nutrition Disorders</td>
<td>Hyperglycaemia</td>
</tr>
<tr>
<td>Psychiatric Disorders</td>
<td>Insomnia, mood changes</td>
</tr>
<tr>
<td>Nervous System Disorders</td>
<td>Hypertonia, hypoesthesia/paresthesia, peripheral neuropathy, syncope, taste p perversion, tremor, extrapyramidal disorder</td>
</tr>
<tr>
<td>Eye Disorders</td>
<td>Visual disturbances</td>
</tr>
</tbody>
</table>
Ear and Labyrinth Disorders   Tinnitus
Vascular Disorders   Hypotension, vasculitis
Respiratory, Thoracic and Mediastinal Disorders   Cough, dyspnoea, rhinitis
Gastrointestinal Disorders   Altered bowel habits, dry mouth, dyspepsia (including gastritis), gingival hyperplasia, pancreatitis, vomiting
Skin and Subcutaneous Tissue Disorders   Alopecia, increased sweating, purpura, skin discolouration, urticaria
Musculoskeletal and Connective Tissue Disorders   Arthralgia, back pain, muscle cramps, myalgia
Renal and Urinary Disorders   Increased urinary frequency, micturition disorder, nocturia
Reproductive System and Breast Disorders   Gynaecomastia, impotence
General Disorders and Administration Site Conditions   Asthenia, malaise, pain
Investigations   Weight increase/decrease

Rarely, allergic reactions including pruritis, rash, angioedema and erythema multiforme have been reported.

Hepatitis, jaundice and hepatic enzyme elevations have also been reported very infrequently (mostly consistent with cholestasis). Some cases severe enough to require hospitalisation have been reported in association with use of amlodipine. In many instances, causal association is uncertain.

As with other calcium channel blockers the following adverse events have been rarely reported and cannot be distinguished from the natural history of the underlying disease: myocardial infarction, arrhythmia (including bradycardia, ventricular tachycardia and atrial fibrillation) and chest pain.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions https://nzphvc.otago.ac.nz/reporting/.

4.9 Overdosage

Available data suggest that overdose might be expected to cause excessive peripheral vasodilatation with marked hypotension and possibly a reflex tachycardia. Dysrhythmias may occur following overdose with any calcium antagonist. Hypotension and bradycardia
are usually seen within 1 to 5 hours following overdose. Hypotension can persist for longer than 24 hours despite treatment. Cardiac rhythm disturbances have been noted to persist for up to 7 days. Marked and probably prolonged systemic hypotension, up to and including shock with fatal outcome, have been reported.

Reports of intentional overdose include a patient who ingested 250 mg and was asymptomatic and was not hospitalised; another (120 mg) was hospitalised, underwent gastric lavage and remained normotensive; a third one (105 mg) was hospitalised and had hypotension (90/50 mmHg) which normalised following plasma expansion. Death resulted from a mixed overdose of 140 mg and 10 mfenamic acid capsules in a 15-year-old girl, and from a mixed overdose of amlodipine 70 mg and an unknown quantity of oxazepam in a 63-year-old woman. A case of accidental drug overdose has been documented in a 19-month-old male who ingested 30 mg NORVASC (about 2 mg/kg). During the emergency room presentation, vital signs were stable with no evidence of hypotension, but a heart rate of 180 bpm.

If massive overdose should occur, active cardiac and respiratory monitoring should be instituted. Frequent blood pressure measurements are essential. Should hypotension occur, cardiovascular support, including elevation of the extremities, and the judicious administration of fluids should be initiated. If hypotension remains unresponsive to these conservative measures, administration of vasopressors (such as phenylephrine), should be considered with attention to circulating volume and urine output. Administration of activated charcoal to healthy volunteers immediately or up to 2 hours after ingestion of NORVASC 10 mg has been shown to significantly decrease amlodipine absorption. In patients who are not fully conscious or have impaired gag reflex, consideration should be given to administering activated charcoal via nasogastric tube once the airway is protected. Ipecac-emesis is not recommended since haemodynamic instability and CNS depression may rapidly develop. Intravenous calcium gluconate may be beneficial in reversing the effects of calcium channel blockade. Dialysis is not likely to be of benefit since amlodipine is highly protein-bound.

For advice on the management of overdose please contact the National Poisons Centre on 0800 POISON (0800 764766).

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Amlodipine is a calcium ion influx inhibitor (slow channel blocker or calcium ion antagonist) and inhibits the transmembrane influx of calcium ions into cardiac and vascular smooth muscle.

The mechanism of the antihypertensive action of amlodipine is due to a direct relaxant effect on vascular smooth muscle.

The precise mechanism by which amlodipine relieves angina has not been fully determined, but amlodipine reduces total ischaemic burden by the following two actions:

1. Amlodipine dilates peripheral arterioles and thus reduces the total peripheral resistance (afterload) against which the heart works. Since the heart rate remains stable, this unloading of the heart reduces myocardial energy consumption and oxygen requirements.
2. The mechanism of action of amlodipine also probably involves dilatation of the main coronary arteries and coronary arterioles, both in normal and ischaemic regions. This dilatation increases myocardial oxygen delivery in patients with coronary artery spasm (Prinzmetal’s or variant angina) and blunts smoking-induced coronary vasoconstriction.

In patients with hypertension, once-daily dosing provides clinically significant reductions in blood pressure in both the supine and standing positions throughout the 24-hour interval.

Due to the slow onset of action, acute hypotension is not a feature of amlodipine administration.

In patients with angina, once-daily administration of amlodipine increases total exercise time, time to angina onset and time to 1 mm ST segment depression, and decreases both angina attack frequency and nitroglycerine tablet consumption.

**Patients with Heart Failure**

Haemodynamic studies and exercise-based controlled clinical trial in NYHA class II-IV heart failure patients have shown that amlodipine did not lead to clinical deterioration as measured by exercise tolerance, left ventricular ejection fraction, and clinical symptomatology.

A placebo-controlled study (PRAISE) designed to evaluate patients with NYHA class III-IV heart failure receiving digoxin, diuretics, and ACE inhibitors has shown that amlodipine did not lead to an increase in risk of mortality or combined mortality and morbidity in patients with heart failure.

In a follow-up, long-term, placebo-controlled study (PRAISE-2) of amlodipine in patients with NYHA class III and IV heart failure without clinical symptoms or objective findings suggestive of underlying ischaemic disease, on stable doses of ACE inhibitors, digitalis and diuretics, amlodipine had no effect on total cardiovascular mortality. In this same population, amlodipine was associated with increased reports of pulmonary oedema despite no significant difference in the incidence of worsening heart failure compared to placebo (see section 4.4).

Amlodipine has not been associated with any adverse metabolic effects or changes in plasma lipids and is suitable for use in patients with asthma, diabetes and gout.

**5.2 Pharmacokinetic properties**

**Absorption**

Amlodipine is well absorbed orally with peak blood levels occurring between 6 and 12 hours post-dose. Oral administration of a single therapeutic dose gave a mean absolute bioavailability of 64% (range 52%-88%). The volume of distribution is approximately 20 L/kg. The absorption of amlodipine is unaffected by consumption of food. *In vitro* studies have shown that approximately 97.5% of circulating amlodipine is bound to plasma proteins.

**Biotransformation/Elimination**

The terminal plasma elimination half-life is about 35 to 50 hours and is consistent with once-daily dosing. Steady-state plasma levels are reached after 7 to 8 days of consecutive dosing. Amlodipine is extensively metabolised by the liver to inactive metabolites, with 10% of the parent compound and 60% of metabolites excreted in the urine.
Amlodipine is not dialysable.

5.3 Preclinical safety data
None stated.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients
Microcrystalline cellulose
Calcium hydrogen phosphate
Sodium starch glycollate
Magnesium stearate.

6.2 Incompatibilities
None stated.

6.3 Shelf life
60 months

6.4 Special precautions for storage
Store below 25°C.
Protect from light.

6.5 Nature and contents of container
The tablets are packaged in PVC/PVdC-Aluminium foil blister packs.
5 mg x 30 tablets.
10 mg x 30 tablets.
6.6 Special precautions for disposal and other handling

None stated.

7. MEDICINE SCHEDULE

Prescription medicine.

8. SPONSOR

Pfizer New Zealand Limited
PO Box 3998
Auckland, New Zealand, 1140

Toll Free Number: 0800-736-363

9. DATE OF FIRST APPROVAL

06 December 1990

10. DATE OF REVISION OF THE TEXT

08 June 2017